MDSCs, myeloid-derived suppressor cells; ILCs, Innate lymphoid cells; NK2, Natural killer; Th2, T helper 2; Treg, regulatory T cells; NKT, natural killer T. Hepatocellular carcinoma (HCC) is a primary ...
Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, Germany, Hengrui presented results from the CARES-009 trial assessing the combination of AiRuiKa ...
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver FailureRamat Gan, Israel, Feb. 05, 2026 ...
A Prescription Drug User Fee Act target date of April 21, 2025 has been assigned to the application. Findings showed the immunotherapy combination significantly improved overall survival (OS; primary ...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have ...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver ...
Ontario becomes the first province in Canada to publicly reimburse the dual immunotherapy combination for unresectable or advanced hepatocellular carcinoma This decision marks the second OPDIVO® ...
Please provide your email address to receive an email when new articles are posted on . Survival for people with HCC has improved over the past decade. Much of the improvement has been limited to ...
Hepatocellular carcinoma (HCC) is a common cancer, and the body’s immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results